Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma.

Autor: Leypoldt LB; Department of Hematology, Oncology & Bone Marrow Transplantation With Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Tichy D; Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany., Besemer B; Department of Hematology, Oncology, Immunology & Rheumatology, University Hospital of Tuebingen, Tuebingen, Germany., Hanel M; Department of Hematology, Oncology & Bone Marrow Transplantation, Klinikum Chemnitz, Chemnitz, Germany., Raab MS; Internal Medicine V & National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany., Mann C; Department of Hematology, Oncology & Immunology, University Hospital of Gießen & Marburg, Marburg, Germany., Munder M; Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany., Reinhardt HC; Department of Hematology & Stem Cell Transplantation, University Hospital Essen, University Duisburg-Essen, German Cancer Consortium (DKTK partner site Essen), Essen, Germany., Nogai A; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin & Humboldt-Universität zu Berlin, Departement of Hematology & Oncology, Germany., Gorner M; Department of Hematology, Oncology & Palliative Care, Klinikum Bielefeld Mitte, Bielefeld, Germany., Ko YD; Department of Internal Medicine, Hematology & Oncology, Johanniter Krankenhaus Bonn, Bonn, Germany., Wit M; Department of Internal Medicine, Hematology, Oncology & Palliative Medicine, Vivantes Klinikum Neukölln, Berlin, Germany., Salwender H; Asklepios Tumorzentrum Hamburg, AK Altona & AK St. Georg, Hamburg, Germany., Scheid C; Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany., Graeven U; Department of Hematology, Oncology & Gastroenterology Kliniken Maria Hilf, Mönchengladbach, Germany., Peceny R; Department of Oncology, Hematology & Stem Cell Transplantation, Klinikum Osnabrück, Osnabrück, Germany., Staib P; Department of Hematology & Oncology, St. Antonius Hospital Eschweiler, Eschweiler, Germany., Dieing A; Department of Hematology & Oncology, Vivantes Klinikum am Urban, Berlin, Germany., Einsele H; Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany., Jauch A; Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany., Hundemer M; Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany., Zago M; Center for Clinical Trials, University Hospital of Tuebingen, Tuebingen, Germany., Pozek E; Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany., Benner A; Division of Biostatistics, German Cancer Research Center (DKFZ) Heidelberg, Heidelberg, Germany., Bokemeyer C; Department of Hematology, Oncology & Bone Marrow Transplantation With Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Goldschmidt H; Internal Medicine V, GMMG-Studygroup at University Hospital Heidelberg, Germany., Weisel KC; Department of Hematology, Oncology & Bone Marrow Transplantation With Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jazyk: angličtina
Zdroj: Future oncology (London, England) [Future Oncol] 2024 Sep 30, pp. 1-15. Date of Electronic Publication: 2024 Sep 30.
DOI: 10.1080/14796694.2024.2402639
Databáze: MEDLINE